301
|
Zhang W, Song J, Mu L, Zhang B, Liu L, Xing Y, Wang K, Li Z, Wang R. Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P. Bioorg Med Chem Lett 2011; 21:1452-5. [PMID: 21282053 DOI: 10.1016/j.bmcl.2011.01.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Revised: 12/29/2010] [Accepted: 01/05/2011] [Indexed: 11/30/2022]
Abstract
Substance P, an 11-residue neuropeptide, can be rapidly internalized through specific interaction with the neurokinin-1 receptor. Therefore, we designed and synthesized the substance P targeted camptothecin (CPT) conjugates via a releasable disulfide carbonate linker. All the conjugates exhibited comparable or stronger cytotoxicity to cancer cells that highly over-express neurokinin-1 receptor than free CPT. More importantly, the selectivity of conjugates was significantly improved compared with CPT. Our results indicated that these conjugates can be promising candidates for new chemotherapeutic drugs. In addition, increasing CPT loading or attachment of CPT to the C-terminal hexapeptide of substance P are useful strategies to enhance the therapeutic efficacy of substance P targeted conjugates.
Collapse
Affiliation(s)
- Wei Zhang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
| | | | | | | | | | | | | | | | | |
Collapse
|
302
|
Blencowe CA, Russell AT, Greco F, Hayes W, Thornthwaite DW. Self-immolative linkers in polymeric delivery systems. Polym Chem 2011. [DOI: 10.1039/c0py00324g] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
303
|
Kularatne SA, Venkatesh C, Santhapuram HKR, Wang K, Vaitilingam B, Henne WA, Low PS. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem 2010; 53:7767-77. [PMID: 20936874 DOI: 10.1021/jm100729b] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Ligand-targeted therapeutics have increased in prominence because of their potential for improved potency and reduced toxicity. However, with the advent of personalized medicine, a need for greater versatility in ligand-targeted drug design has emerged, where each tumor-targeting ligand should be capable of delivering a variety of therapeutic agents to the same tumor, each therapeutic agent being selected for its activity on a specific patient's cancer. In this report, we describe the use of a prostate-specific membrane antigen (PSMA)-targeting ligand to deliver multiple unrelated cytotoxic drugs to human prostate cancer (LNCaP) cells. We demonstrate that the PSMA-specific ligand, 2-[3-(1, 3-dicarboxy propyl)ureido] pentanedioic acid, is capable of mediating the targeted killing of LNCaP cells with many different therapeutic warheads. These results suggest that flexibility can be designed into ligand-targeted therapeutics, enabling adaptation of a single targeting ligand for the treatment of patients with different sensitivities to different chemotherapies.
Collapse
Affiliation(s)
- Sumith A Kularatne
- Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States
| | | | | | | | | | | | | |
Collapse
|
304
|
Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Ajaj KA, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H, Kratz F. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: An in vitro and in vivo evaluation study. Eur J Cancer 2010; 46:3434-44. [DOI: 10.1016/j.ejca.2010.08.018] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2010] [Accepted: 08/24/2010] [Indexed: 11/27/2022]
|
305
|
Rigaud O, Fortunel NO, Vaigot P, Cadio E, Martin MT, Lundh O, Faure J, Rechatin C, Malka V, Gauduel YA. Exploring ultrashort high-energy electron-induced damage in human carcinoma cells. Cell Death Dis 2010; 1:e73. [PMID: 21364677 PMCID: PMC3032345 DOI: 10.1038/cddis.2010.46] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- O Rigaud
- Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, CEA, 2 rue G. Crémieux, Evry 91057, France
| | - N O Fortunel
- Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, CEA, 2 rue G. Crémieux, Evry 91057, France
| | - P Vaigot
- Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, CEA, 2 rue G. Crémieux, Evry 91057, France
| | - E Cadio
- Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, CEA, 2 rue G. Crémieux, Evry 91057, France
| | - M T Martin
- Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, CEA, 2 rue G. Crémieux, Evry 91057, France
| | - O Lundh
- LOA, CNRS UMR 7639, Ecole Polytechnique Paris Tech, ENSTA Paris Tech, Palaiseau Cedex 91761, France
| | - J Faure
- LOA, CNRS UMR 7639, Ecole Polytechnique Paris Tech, ENSTA Paris Tech, Palaiseau Cedex 91761, France
| | - C Rechatin
- LOA, CNRS UMR 7639, Ecole Polytechnique Paris Tech, ENSTA Paris Tech, Palaiseau Cedex 91761, France
| | - V Malka
- LOA, CNRS UMR 7639, Ecole Polytechnique Paris Tech, ENSTA Paris Tech, Palaiseau Cedex 91761, France
| | - Y A Gauduel
- LOA, CNRS UMR 7639, Ecole Polytechnique Paris Tech, ENSTA Paris Tech, Palaiseau Cedex 91761, France
| |
Collapse
|
306
|
Mhidia R, Bézière N, Blanpain A, Pommery N, Melnyk O. Assembly/Disassembly of Drug Conjugates Using Imide Ligation. Org Lett 2010; 12:3982-5. [DOI: 10.1021/ol101049g] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Reda Mhidia
- UMR CNRS 8161, Université de Lille Nord de France, IFR 142, Institut Pasteur de Lille, 1 rue du Pr Calmette 59021 Lille, France, and Université de Lille Nord de France, 3 rue du Professeur Laguesse BP83, 59006 Lille Cedex, France
| | - Nicolas Bézière
- UMR CNRS 8161, Université de Lille Nord de France, IFR 142, Institut Pasteur de Lille, 1 rue du Pr Calmette 59021 Lille, France, and Université de Lille Nord de France, 3 rue du Professeur Laguesse BP83, 59006 Lille Cedex, France
| | - Annick Blanpain
- UMR CNRS 8161, Université de Lille Nord de France, IFR 142, Institut Pasteur de Lille, 1 rue du Pr Calmette 59021 Lille, France, and Université de Lille Nord de France, 3 rue du Professeur Laguesse BP83, 59006 Lille Cedex, France
| | - Nicole Pommery
- UMR CNRS 8161, Université de Lille Nord de France, IFR 142, Institut Pasteur de Lille, 1 rue du Pr Calmette 59021 Lille, France, and Université de Lille Nord de France, 3 rue du Professeur Laguesse BP83, 59006 Lille Cedex, France
| | - Oleg Melnyk
- UMR CNRS 8161, Université de Lille Nord de France, IFR 142, Institut Pasteur de Lille, 1 rue du Pr Calmette 59021 Lille, France, and Université de Lille Nord de France, 3 rue du Professeur Laguesse BP83, 59006 Lille Cedex, France
| |
Collapse
|
307
|
Elsadek B, Graeser R, Warnecke A, Unger C, Saleem T, El-Melegy N, Madkor H, Kratz F. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen. ACS Med Chem Lett 2010; 1:234-8. [PMID: 24900200 DOI: 10.1021/ml100060m] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2010] [Accepted: 05/03/2010] [Indexed: 11/28/2022] Open
Abstract
We have developed a novel albumin-binding prodrug of doxorubicin that incorporates p-aminobenzyloxycarbonyl (PABC) as a 1,6 self-immolative spacer in addition to the heptapeptide, Arg-Ser-Ser-Tyr-Tyr-Ser-Leu, as a substrate for the prostate-specific antigen (PSA) that is overexpressed in prostate carcinoma and represents a molecular target for selectively releasing an anticancer agent from a prodrug formulation. The prodrug exhibited good water solubility and was bound rapidly to the cysteine-34 position of human serum albumin. Incubation studies with PSA demonstrated that the albumin-bound form of the prodrug was cleaved rapidly at the P1-P1' scissile bond, releasing H-Ser-Leu-PABC-DOXO, which was further degraded to release doxorubicin as a final cleavage product within a few hours in prostate tumor tissue homogenates as well as in PSA-positive LNCaP LN cell lysates. Moreover, our prodrug exhibited antiproliferative activity in a low micromolar range against a PSA-expressing prostate cancer cell line (LNCaP).
Collapse
Affiliation(s)
- Bakheet Elsadek
- Tumor Biology Center, Division of Macromolecular Prodrugs, Breisacher Strasse 117, 79106 Freiburg, Germany
- Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, P.O. Box No. 71524, Assiut, Egypt
| | - Ralph Graeser
- ProQinase GmbH, Breisacher Strasse 117, 79106 Freiburg, Germany
| | - André Warnecke
- Tumor Biology Center, Division of Macromolecular Prodrugs, Breisacher Strasse 117, 79106 Freiburg, Germany
| | - Clemens Unger
- Tumor Biology Center, Division of Macromolecular Prodrugs, Breisacher Strasse 117, 79106 Freiburg, Germany
| | - Tahia Saleem
- Department of Biochemistry, Faculty of Medicine, Assiut University, P.O. Box No. 71526, Assiut, Egypt
| | - Nagla El-Melegy
- Department of Biochemistry, Faculty of Medicine, Assiut University, P.O. Box No. 71526, Assiut, Egypt
| | - Hafez Madkor
- Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, P.O. Box No. 71524, Assiut, Egypt
| | - Felix Kratz
- Tumor Biology Center, Division of Macromolecular Prodrugs, Breisacher Strasse 117, 79106 Freiburg, Germany
| |
Collapse
|
308
|
Müller IA, Kratz F, Jung M, Warnecke A. Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.06.055] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
309
|
Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 2010; 132:4678-84. [PMID: 20225865 PMCID: PMC3662397 DOI: 10.1021/ja908117a] [Citation(s) in RCA: 512] [Impact Index Per Article: 36.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
![]()
The platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin are an important component of chemotherapy but are limited by severe dose-limiting side effects and the ability of tumors to develop resistance rapidly. These drugs can be improved through the use of drug-delivery vehicles that are able to target cancers passively or actively. In this study, we have tethered the active component of the anticancer drug oxaliplatin to a gold nanoparticle for improved drug delivery. Naked gold nanoparticles were functionalized with a thiolated poly(ethylene glycol) (PEG) monolayer capped with a carboxylate group. [Pt(1R,2R-diaminocyclohexane)(H2O)2]2NO3 was added to the PEG surface to yield a supramolecular complex with 280 (±20) drug molecules per nanoparticle. The platinum-tethered nanoparticles were examined for cytotoxicity, drug uptake, and localization in the A549 lung epithelial cancer cell line and the colon cancer cell lines HCT116, HCT15, HT29, and RKO. The platinum-tethered nanoparticles demonstrated as good as, or significantly better, cytotoxicity than oxaliplatin alone in all of the cell lines and an unusual ability to penetrate the nucleus in the lung cancer cells.
Collapse
Affiliation(s)
- Sarah D Brown
- Centre for Molecular Nanometrology, Department of Pure and Applied Chemistry, Thomas Graham Building, University of Strathclyde, 295 Cathedral Street, G1 1XL Glasgow, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
310
|
Etrych T, Šírová M, Starovoytova L, Říhová B, Ulbrich K. HPMA Copolymer Conjugates of Paclitaxel and Docetaxel with pH-Controlled Drug Release. Mol Pharm 2010; 7:1015-26. [DOI: 10.1021/mp100119f] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Tomáš Etrych
- Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, and Laboratory of Tumor Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
| | - Milada Šírová
- Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, and Laboratory of Tumor Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
| | - L. Starovoytova
- Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, and Laboratory of Tumor Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
| | - Blanka Říhová
- Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, and Laboratory of Tumor Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
| | - Karel Ulbrich
- Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, and Laboratory of Tumor Immunology, Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
| |
Collapse
|
311
|
Harper B, Krause-Heuer A, Grant M, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright J. Advances in Platinum Chemotherapeutics. Chemistry 2010; 16:7064-77. [DOI: 10.1002/chem.201000148] [Citation(s) in RCA: 228] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
312
|
Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010; 21:5-13. [PMID: 19769391 DOI: 10.1021/bc9002019] [Citation(s) in RCA: 439] [Impact Index Per Article: 31.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.
Collapse
|
313
|
Chevalier S, Goupille C, Mahéo K, Domingo I, Dussiau C, Renoux B, Bougnoux P, Papot S. Dietary docosahexaenoic acid proposed to sensitize breast tumors to locally delivered drug. ACTA ACUST UNITED AC 2010. [DOI: 10.2217/clp.10.12] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
314
|
Wu W, Hsiao SC, Carrico ZM, Francis MB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed Engl 2010; 48:9493-7. [PMID: 19921725 DOI: 10.1002/anie.200902426] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Wesley Wu
- Department of Chemistry, University of California, Berkeley and Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-1460, USA
| | | | | | | |
Collapse
|
315
|
Vetvicka D, Hruby M, Hovorka O, Etrych T, Vetrik M, Kovar L, Kovar M, Ulbrich K, Rihova B. Biological evaluation of polymeric micelles with covalently bound doxorubicin. Bioconjug Chem 2010; 20:2090-7. [PMID: 19835372 DOI: 10.1021/bc900212k] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The main limitation of contemporary anticancer chemotherapy remains to be the insufficient specificity of the drugs for tumor tissue, which decreases the maximum tolerated dose due to severe side effects. Micellar drug delivery systems based on amphiphilic block copolymers with a very narrow size distribution (10 to 100 nm in diameter) is a novel innovative approach. Here, we report biological and pharmacological properties of polymeric micellar conjugate containing doxorubicin (DOX) covalently bound via hydrolytically cleavable hydrazone bonds to the micelle core. The system had a very low systemic toxicity (almost 20 times lower than free DOX) and long circulation in the bloodstream (with half of the dose after 24 h). Significant accumulation of tested micelles within the tumor was confirmed by fluorescent whole body imaging. Our new micellar system showed promising therapeutic activity against established murine EL-4 T-cell lymphoma; it was found that it is able to completely cure about 75% of tumor-bearing mice (with doses of either 1 x 150 mg DOX kg(-1) or 2 x 75 mg DOX kg(-1), administered i.v.). Moreover, treatment with micelles in cured mice induced tumor-specific resistance. Up to 80% of these mice survived rechallenge with original but not with distinct tumor cells.
Collapse
Affiliation(s)
- David Vetvicka
- Institute of Microbiology AS CR, v.v.i., Videnska 1083, 14220 Prague 4, Czech Republic.
| | | | | | | | | | | | | | | | | |
Collapse
|
316
|
Kaasgaard T, Andresen TL. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 2010; 7:225-43. [DOI: 10.1517/17425240903427940] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
317
|
Meyer Y, Richard JA, Delest B, Noack P, Renard PY, Romieu A. A comparative study of the self-immolation of para-aminobenzylalcohol and hemithioaminal-based linkers in the context of protease-sensitive fluorogenic probes. Org Biomol Chem 2010; 8:1777-80. [DOI: 10.1039/b926316k] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
318
|
Kurosu M, Li K. MILD AND SELECTIVE O-GLYCOSYLATIONS OF PRIMARY ALCOHOLS WITH THE THIOGLUCOSAMINIDE DERIVATIVE PROMOTED BY N-IODOSUCCINIMIDE AND HBF(4)-ADOSROBED ON SILICA GEL. HETEROCYCLES 2010; 80:115-123. [PMID: 23239901 PMCID: PMC3518929 DOI: 10.3987/com-09-s(s)24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Selective glycosylations of primary alcohols with the thioglucosaminide 1 are achieved by using NIS and HBF(4)-SiO(2). HBF(4)-SiO(2) is a mild Brønsted acid which requires primary alcohols or phenols to effectively activate 1 with NIS at rt. A wide range of functional groups are tolerated under these conditions.
Collapse
Affiliation(s)
- Michio Kurosu
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1682 Campus Delivery, Fort Collins, CO 80523-1682, USA
| | - Kai Li
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1682 Campus Delivery, Fort Collins, CO 80523-1682, USA
| |
Collapse
|
319
|
Sun H, Chai ZF. Metallomics: An integrated science for metals in biology and medicine. ACTA ACUST UNITED AC 2010. [DOI: 10.1039/b920672h] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
320
|
Minko T, Patil ML, Zhang M, Khandare JJ, Saad M, Chandna P, Taratula O. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol 2010; 624:281-294. [PMID: 20217603 DOI: 10.1007/978-1-60761-609-2_19] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Synthesis and evaluation of a novel cancer cell's receptor-targeted internally quaternized and surface neutral poly(amidoamine) (PAMAM) generation four dendrimer as well as PAMAM-paclitaxel conjugate are described. The advantages of developed nanocarriers include but are not limited to (1) internal cationic charges for the complexation with small interfering RNA or antisense oligonucleotides and their protection from the degradation in systemic circulation; (2) neutral-modified surface for low cytotoxicity of empty unloaded dendrimers; (3) efficient internalization by cancer cells; and (4) preferential accumulation in the tumor and the prevention of adverse side effects of chemotherapy.
Collapse
Affiliation(s)
- Tamara Minko
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, USA
| | | | | | | | | | | | | |
Collapse
|
321
|
Simerska P, Moyle PM, Toth I. Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev 2009; 31:520-47. [DOI: 10.1002/med.20191] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
322
|
|
323
|
Zhang XB, Waibel M, Hasserodt J. An Autoimmolative Spacer Allows First-Time Incorporation of a Unique Solid-State Fluorophore into a Detection Probe for Acyl Hydrolases. Chemistry 2009; 16:792-5. [DOI: 10.1002/chem.200902412] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
324
|
Wu W, Hsiao S, Carrico Z, Francis M. Genome-Free Viral Capsids as Multivalent Carriers for Taxol Delivery. Angew Chem Int Ed Engl 2009. [DOI: 10.1002/ange.200902426] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
325
|
Rihova B. Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates. Adv Drug Deliv Rev 2009; 61:1149-58. [PMID: 19682512 DOI: 10.1016/j.addr.2008.12.017] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Accepted: 12/19/2008] [Indexed: 10/20/2022]
Abstract
This paper reviews an early clinical experience with anthracycline (epirubicin; Epi or doxorubicin; Dox) containing an N-(2-hydroyxypropyl)methacrylamide copolymer carrier targeted with autologous or commercial human immunoglobulin in six patients aged 28-55 suffering from therapy-resistant metastatic cancer. More than 100 biochemical, hematological and immunological parameters, including nine tumor markers, were tested in blood samples taken 24 h after the first and up to 10 months after the last application. The intravenous application proceeded without serious adverse or side effects and did not require hospitalization. Cardiotoxicity was not observed. Four of six monitored patients attained stabilization of disease (liver ultrasound scan and bone computer tomography) with a very good quality of life lasting from seven up to 18 months. Positive response to the treatment was, among others, evaluated as decreased CA 15-3 and CEA tumor markers. In three of five tested patients the serum level of C-reactive protein was temporarily increased 72 h after the treatment. A stable or elevated number of peripheral blood reticulocytes together with activation of natural killer (NK) cells and lymphokine-activated killer (LAK) cells supports the data previously obtained in experimental animals pointing to a dual role, i.e. the cytotoxic and immunomobilizing character of doxorubicin-HPMA conjugates.
Collapse
|
326
|
Melisi D, Rosso F, Curcio A, Tortora C, Nieddu M, Marino G, Lettieri M, Grimaldi A, Luongo E, Romano S, Romano MF, Boatto G, Abignente E, Barbarisi A, Rimoli MG. Galactosyl derivative ofNω-nitro-L-arginine: Study of antiproliferative activity on human thyroid follicular carcinoma cells. J Cell Physiol 2009; 221:440-7. [DOI: 10.1002/jcp.21876] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
327
|
Etrych T, Strohalm J, Kovář L, Kabešová M, Říhová B, Ulbrich K. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity. J Control Release 2009; 140:18-26. [DOI: 10.1016/j.jconrel.2009.07.011] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2009] [Revised: 07/13/2009] [Accepted: 07/15/2009] [Indexed: 11/27/2022]
|
328
|
Burakowska E, Zimmerman SC, Haag R. Photoresponsive crosslinked hyperbranched polyglycerols as smart nanocarriers for guest binding and controlled release. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2009; 5:2199-2204. [PMID: 19572327 DOI: 10.1002/smll.200900465] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A convenient methodology for the synthesis of photolabile crosslinked hyperbranched polyglycerol nanocapsules is presented. These nanocarriers selectively and efficiently bind ionic guest molecules. The stability of the host-guest complexes formed depends on the counterion of the guest molecules. Moreover, the control over guest binding can be achieved by modification of the polymer building blocks, in particular the outer shell. In addition, photo-triggered degradation of the nanocarrier leads to efficient release of encapsulated guest molecules. This approach, using photolabile dendritic nanocarriers to bind and release guest molecules, is of particular relevance for biomedical applications where selective guest binding and controlled release are crucial.
Collapse
Affiliation(s)
- Ewelina Burakowska
- Department of Biology, Chemistry, and Pharmacy, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany
| | | | | |
Collapse
|
329
|
Tietze LF, Krewer B. Antibody-Directed Enzyme Prodrug Therapy: A Promising Approach for a Selective Treatment of Cancer Based on Prodrugs and Monoclonal Antibodies. Chem Biol Drug Des 2009; 74:205-11. [DOI: 10.1111/j.1747-0285.2009.00856.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
330
|
Synthesis and antitumor activity of amino acid ester derivatives containing 5-fluorouracil. Molecules 2009; 14:3142-52. [PMID: 19783913 PMCID: PMC6254981 DOI: 10.3390/molecules14093142] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2009] [Revised: 08/18/2009] [Accepted: 08/20/2009] [Indexed: 12/28/2022] Open
Abstract
A series of amino acid ester derivatives containing 5-fluorouracil were synthesized using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and N-hydroxybenzotriazole (HOBt) as a coupling agent. The structures of the products were assigned by NMR, MS, IR etc. The in vitro antitumor activity tests against leukaemia HL-60 and liver cancer BEL-7402 indicated that (R)-ethyl 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-3-(4-hydroxyphenyl) propanoate showed more inhibitory effect against BEL-7402 than 5-FU.
Collapse
|
331
|
Bruijnincx PCA, Sadler PJ. Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. ADVANCES IN INORGANIC CHEMISTRY 2009; 61:1-62. [PMID: 21258628 PMCID: PMC3024542 DOI: 10.1016/s0898-8838(09)00201-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - Peter J. Sadler
- Department of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom
| |
Collapse
|
332
|
Gerspach J, Pfizenmaier K, Wajant H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 2009; 35:364-72. [PMID: 19484741 DOI: 10.1002/biof.50] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Tumor necrosis factor (TNF) is highly pleiotropic cytokine regulating diverse cellular processes such as proliferation, cell migration, angiogenesis, differentiation, apoptosis, necrosis, but also survival. Because of its name-giving tumor necrosis-inducing capabilities, TNF has attracted attention very early for antitumor therapy. Although TNF is in clinical use for treatment of soft tissue sarcoma in isolated limb perfusion, its broad use in tumor therapy is prevented so far by its strong systemic proinflammatory effects. Nevertheless, over the past decade, a variety of tailor-made TNF variants have been developed with the aim to reduce TNFs systemic activity without losing its antitumoral effects. Here, we review the progress made toward improving the efficacy of TNF by genetic engineering, tumor targeting, and introduction of prodrug concepts.
Collapse
Affiliation(s)
- Jeannette Gerspach
- Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
| | | | | |
Collapse
|
333
|
Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol. Bioorg Med Chem Lett 2009; 19:3725-8. [DOI: 10.1016/j.bmcl.2009.05.058] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2009] [Revised: 05/13/2009] [Accepted: 05/14/2009] [Indexed: 11/18/2022]
|
334
|
Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo JL, Weissleder R, Kohler R, Yaffe MB, Cantley LC, Josephson L. The antiproliferative cytostatic effects of a self-activating viridin prodrug. Mol Cancer Ther 2009; 8:1666-75. [PMID: 19509266 PMCID: PMC2740925 DOI: 10.1158/1535-7163.mct-08-1012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Although viridins like wortmannin (Wm) have long been examined as anticancer agents, their ability to self-activate has only recently been recognized. Here, we describe the cytostatic effects of a self-activating viridin (SAV), which is an inactive, polymeric prodrug. SAV self-activates to generate a bioactive, fluorescent viridin NBD-Wm with a half-time of 9.2 hours. With cultured A549 cells, 10 micromol/L SAV caused growth arrest without inducing apoptosis or cell death, a cytostatic action markedly different from other chemotherapeutic agents (vinblastine, camptothecin, and paclitaxel). In vivo, a SAV dosing of 1 mg/kg once in 48 hours (i.p.) resulted in growth arrest of an A549 tumor xenograft, with growth resuming when dosing ceased. With a peak serum concentration of SAV of 2.36 micromol/L (at 2 hours post i.p. injection), the concentration of bioactive NBD-Wm was 41 nmol/L based on the partial inhibition of neutrophil respiratory burst. Therefore, SAV was present as an inactive prodrug in serum (peak = 2.36 micromol/L), which generated low concentrations of active viridin (41 nmol/L). SAV is a prodrug, the slow release and cytostatic activities of which suggest that it might be useful as a component of metronomic-based chemotherapeutic strategies.
Collapse
Affiliation(s)
- Adam Smith
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Joseph Blois
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Hushan Yuan
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Elena Aikawa
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Christian Ellson
- Koch Institute for Integrative Cancer Research, Department of Biology, Cambridge, Massachusetts
| | - Jose-Luiz Figueiredo
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Ralph Weissleder
- Department of Systems Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Louis Pasteur, Boston, Massachusetts
| | - Rainer Kohler
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - Michael B. Yaffe
- Koch Institute for Integrative Cancer Research, Department of Biology, Cambridge, Massachusetts
| | - Lewis C. Cantley
- Department of Systems Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Louis Pasteur, Boston, Massachusetts
| | - Lee Josephson
- Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| |
Collapse
|
335
|
Jiang Y, DiPaola RS, Hu L. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorg Med Chem Lett 2009; 19:2587-90. [DOI: 10.1016/j.bmcl.2009.03.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Revised: 03/03/2009] [Accepted: 03/04/2009] [Indexed: 10/21/2022]
|
336
|
Koide Y, Urano Y, Yatsushige A, Hanaoka K, Terai T, Nagano T. Design and Development of Enzymatically Activatable Photosensitizer Based on Unique Characteristics of Thiazole Orange. J Am Chem Soc 2009; 131:6058-9. [DOI: 10.1021/ja900443b] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Yuichiro Koide
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| | - Yasuteru Urano
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| | - Akira Yatsushige
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| | - Kenjiro Hanaoka
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| | - Takuya Terai
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| | - Tetsuo Nagano
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, and CREST, JST, and PRESTO, JST, Japan Science and Technology Agency, 3-5 Sanbancho, Chiyoda, Tokyo 102-0075, Japan
| |
Collapse
|
337
|
|
338
|
Law B, Tung CH. Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and Imaging. Bioconjug Chem 2009; 20:1683-95. [DOI: 10.1021/bc800500a] [Citation(s) in RCA: 109] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Benedict Law
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58105, and The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas 77030
| | - Ching-Hsuan Tung
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58105, and The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, Texas 77030
| |
Collapse
|
339
|
Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR, Collins JG. Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J Inorg Biochem 2009; 103:373-80. [DOI: 10.1016/j.jinorgbio.2008.11.014] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2008] [Revised: 10/20/2008] [Accepted: 11/24/2008] [Indexed: 11/24/2022]
|
340
|
Gauthier C, Legault J, Rondeau S, Pichette A. Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2008.12.043] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
341
|
Xu S, Luo Y, Graeser R, Warnecke A, Kratz F, Hauff P, Licha K, Haag R. Development of pH-responsive core–shell nanocarriers for delivery of therapeutic and diagnostic agents. Bioorg Med Chem Lett 2009; 19:1030-4. [DOI: 10.1016/j.bmcl.2008.01.043] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2007] [Revised: 01/09/2008] [Accepted: 01/12/2008] [Indexed: 10/22/2022]
|
342
|
Ge Y, Wu X, Zhang D, Hu L. 3-Aminoxypropionate-based linker system for cyclization activation in prodrug design. Bioorg Med Chem Lett 2009; 19:941-4. [DOI: 10.1016/j.bmcl.2008.11.097] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2008] [Revised: 11/23/2008] [Accepted: 11/24/2008] [Indexed: 12/01/2022]
|
343
|
Ajaj KA, Biniossek ML, Kratz F. Development of Protein-Binding Bifunctional Linkers for a New Generation of Dual-Acting Prodrugs. Bioconjug Chem 2009; 20:390-6. [DOI: 10.1021/bc800429q] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Khalid Abu Ajaj
- Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, and Institute of Molecular Medicine and Cell Research, Zentrum für Biochemie and Molekulare Zellforschung, Stefan-Meier-Strasse 17, 79104 Freiburg, Germany
| | - Martin L. Biniossek
- Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, and Institute of Molecular Medicine and Cell Research, Zentrum für Biochemie and Molekulare Zellforschung, Stefan-Meier-Strasse 17, 79104 Freiburg, Germany
| | - Felix Kratz
- Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, and Institute of Molecular Medicine and Cell Research, Zentrum für Biochemie and Molekulare Zellforschung, Stefan-Meier-Strasse 17, 79104 Freiburg, Germany
| |
Collapse
|
344
|
Graeser R, Esser N, Unger H, Fichtner I, Zhu A, Unger C, Kratz F. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 2009; 28:14-9. [PMID: 19148580 DOI: 10.1007/s10637-008-9208-2] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2008] [Accepted: 12/08/2008] [Indexed: 10/21/2022]
Abstract
The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that is being assessed clinically. The prodrug binds rapidly to circulating serum albumin and releases doxorubicin selectively at the tumor site. This novel mechanism may provide enhanced antitumor activity of doxorubicin while improving the overall toxicity profile. Preclinically, INNO-206 has shown superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. In this work, we compared the antitumor activity of INNO-206 and doxorubicin at their respective maximum tolerated doses in three additional xenograft models (breast carcinoma 3366, ovarian carcinoma A2780, and small cell lung cancer H209) as well as in an orthotopic pancreas carcinoma model (AsPC-1). INNO-206 showed more potent antitumor efficacy than free doxorubicin in all tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors.
Collapse
Affiliation(s)
- R Graeser
- Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, 79106, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
345
|
Palombo M, Singh Y, Sinko P. Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy. J Drug Deliv Sci Technol 2009; 19:3-14. [DOI: 10.1016/s1773-2247(09)50001-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
346
|
Richard JA, Jean L, Schenkels C, Massonneau M, Romieu A, Renard PY. Self-cleavable chemiluminescent probes suitable for protease sensing. Org Biomol Chem 2009; 7:2941-57. [DOI: 10.1039/b905725k] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
347
|
Li S, Ma Y, Yue X, Cao Z, Dai Z. One-pot construction of doxorubicin conjugated magnetic silica nanoparticles. NEW J CHEM 2009. [DOI: 10.1039/b9nj00342h] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
348
|
Ríhová B, Kovár L, Kovár M, Hovorka O. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics. Trends Biotechnol 2008; 27:11-7. [PMID: 19022512 DOI: 10.1016/j.tibtech.2008.10.006] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Revised: 08/29/2008] [Accepted: 10/08/2008] [Indexed: 12/22/2022]
Abstract
The successful treatment of cancer with conventional drugs is frequently complicated by the resistance of tumor cells to such a non-specific therapy. Over the last few years, immunotherapy has gained attention as a tumor-specific approach. Recent findings demonstrated that some conventional cytostatics stimulate local anticancer responses. New anticancer drugs, including their polymeric derivatives, are currently being developed with the aim of destroying tumors more effectively and more specifically. Among these, the water-soluble conjugates of doxorubicin with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier have emerged as efficient therapeutics because they are able to not only directly destroy cancer cells but also elicit systemic tumor-specific anticancer responses. Here, we discuss new insights into their mechanisms of immune surveillance, which could suggest novel approaches to cancer therapy.
Collapse
Affiliation(s)
- Blanka Ríhová
- Institute of Microbiology Academy of Sciences of the Czech Republic, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
| | | | | | | |
Collapse
|
349
|
Kwon YM, Li Y, Naik S, Liang JF, Huang Y, Park YJ, Yang VC. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Deliv 2008; 5:1255-66. [DOI: 10.1517/17425240802498059] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
350
|
Ryppa C, Mann-Steinberg H, Biniossek ML, Satchi-Fainaro R, Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm 2008; 368:89-97. [PMID: 18992308 DOI: 10.1016/j.ijpharm.2008.09.055] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2008] [Revised: 09/29/2008] [Accepted: 09/30/2008] [Indexed: 12/31/2022]
Abstract
The alpha(v)beta(3) integrin is overexpressed on proliferating endothelial cells such as those present in growing tumors as well as on tumor cells of various origins. Tumor-induced angiogenesis can be inhibited in vivo by antagonizing the alpha(v)beta(3) integrin with small peptides containing the arginyl-glycyl-aspartic acid (RGD) amino acid sequence. The divalent cyclic peptide E-[c(RGDfK)(2)] is a novel ligand-based vascular-targeting agent that binds integrin alpha(v)beta(3) and demonstrated high uptake in OVCAR-3 xenograft tumors. In this work, we coupled the 2'-OH-group of paclitaxel through an aliphatic ester to the amino group of E-[c(RGDfK)(2)] or the control peptide c(RADfK), thus obtaining the derivatives E-[c(RGDfK)(2)]-paclitaxel and c(RADfK)-paclitaxel. Subsequently, we investigated the activity of the paclitaxel derivatives using several well-established in vitro angiogenesis assays: using a standard 72 h endothelial cell proliferation assay, we showed that both E-[c(RGDfK)(2)]-paclitaxel and c(RADfK)-paclitaxel inhibit the proliferation of human umbilical vein endothelial cells (HUVEC) in a similar manner as free paclitaxel (IC(50) value approximately 0.4 nM), an observation that can be explained by the half-life of the paclitaxel ester bond in the conjugates of approximately 2h at pH 7. In contrast, a 30-min exposure of the cells to the three drugs showed a clear difference between free paclitaxel, E-[c(RGDfK)(2)]-paclitaxel and c(RADfK)-paclitaxel with IC(50) values of 10nM, 25 nM, and 60 nM, respectively. These differences are very likely due to the different routes of cellular entry of these three molecules. While the hydrophobic paclitaxel diffuses rapidly through the cell membrane, the charged peptide-containing derivative E-[c(RGDfK)(2)]-paclitaxel binds to the overexpressed alpha(v)beta(3) integrin in order to enter the cells via receptor-mediated endocytosis. The differences between the derivatives were further demonstrated using an endothelial cell adhesion assay. Inhibition of cell attachment was observed only with the E-[c(RGDfK)(2)]-paclitaxel derivative indicating its specificity to the growing endothelial cells. Furthermore, E-[c(RGDfK)(2)]-paclitaxel inhibited both endothelial cells migration and capillary-like tube formation. These results further demonstrate their antiangiogenic properties. In vivo studies in an OVCAR-3 xenograft model demonstrated no antitumor efficacy for either E-[c(RGDfK)(2)] or E-[c(RGDfK)(2)]-paclitaxel compared to moderate efficacy for paclitaxel.
Collapse
Affiliation(s)
- Claudia Ryppa
- Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Federal Republic of Germany
| | | | | | | | | |
Collapse
|